Varicella-Zoster Virus Vaccine News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

C.D.C. Panel Recommends a New Shingles Vaccine
Shingrix is considered much more effective than the older vaccine, Zostavax. Health officials urged consumers over age 50 to be vaccinated. (Source: NYT Health)
Source: NYT Health - October 25, 2017 Category: Consumer Health News Authors: SHEILA KAPLAN Tags: Shingles (Disease) Vaccination and Immunization Advisory Committee on Immunization Practices Centers for Disease Control and Prevention Source Type: news

U.S. committee recommends GSK shingles vaccine over Merck rival
LONDON (Reuters) - The committee responsible for U.S. vaccination schedules has given a preferential recommendation to GlaxoSmithKline's newly approved shingles vaccine Shingrix over Merck& Co's established product Zostavax. (Source: Reuters: Health)
Source: Reuters: Health - October 25, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves New Herpes Zoster Vaccine (FREE)
By the Editors The FDA has approved a second vaccine to prevent herpes zoster in adults aged 50 and older, the manufacturer announced on Friday. … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 23, 2017 Category: Primary Care Source Type: news

Shingrix (zoster vaccine recombinant, adjuvanted) Approved in the U.S. for Prevention of Shingles
London UK 20 October 2017 -- GlaxoSmithKline plc [LSE/NYSE: GSK] today announced that the US Food and Drug Administration (FDA) has approved Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 20, 2017 Category: Drugs & Pharmacology Source Type: news

GSK ’s Shingrix receives approval in Canada to prevent shingles
GlaxoSmithKline ’s (GSK) non-live, recombinant sub-unit, adjuvanted vaccine Shingrix has received approval from Health Canada to prevent shingles (herpes zoster) in people aged 50 or older. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 15, 2017 Category: Pharmaceuticals Source Type: news

Most Popular NEJM Group Feature This Week: New Zoster Vaccine Worth Waiting For (FREE)
By the Editors Here ' s the most clicked-on item we featured from NEJM … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 22, 2017 Category: Primary Care Source Type: news

From the Blogs: New Zoster Vaccine Worth Waiting For / Benefits & Risks of Curbside Consults (FREE)
By the Editors Take a look at what the NEJM Journal Watch bloggers are talking … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 18, 2017 Category: Primary Care Source Type: news

FDA Advisers Recommend Approval of New Shingles Vaccine (FREE)
By the Editors An FDA advisory panel voted 11-0 on Wednesday in favor of approving the Shingrix herpes zoster vaccine for adults … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 14, 2017 Category: Primary Care Source Type: news

US FDA advisory committee votes for GSK ’s Shingrix to prevent shingles
The US Food and Drug Administration ’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) has voted unanimously for GlaxoSmithKline’s (GSK) Shingrix (HZ/su) to prevent herpes zoster (shingles) in adults of 50 years of age and a… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 13, 2017 Category: Pharmaceuticals Source Type: news

FDA Panel Recommends New Shingles Vaccine FDA Panel Recommends New Shingles Vaccine
An FDA panel unanimously recommended zoster vaccine recombinant (adjuvanted) (Shingrix, GlaxoSmithKline) for adults aged 50 years and older.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2017 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

FDA Advisory Committee Votes Unanimously for Shingrix (HZ/su) in the US for Prevention of Herpes Zoster (Shingles) in Adults Ages 50 and Over
London UK 13 September 2017 -- GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the US Food and Drug Administration (FDA) voted unanimously that the data support the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - September 13, 2017 Category: Drugs & Pharmacology Source Type: news

Tofacitinib After Live Shingles Vaccination Does Not Impair Immunogenicity Tofacitinib After Live Shingles Vaccination Does Not Impair Immunogenicity
Tofacitinib begun 2 to 3 weeks after live zoster vaccination does not impair immunogenicity, and vaccination appears to be safe in patients with pre-existing varicella-zoster virus (VZV) immunity, researchers report.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - August 31, 2017 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

New Herpes Zoster Vaccine Close to FDA Approval
A new recombinant adjuvanted herpes zoster vaccine awaiting potential approval from the Food and Drug Administration has been shown to have close to 90% efficacy at 4 years among research participants older than 70 and even those older than 80. (Source: Caring for the Ages)
Source: Caring for the Ages - August 30, 2017 Category: Health Management Authors: Christine Kilgore Source Type: news

Shingles Vax Effective in RA Patients onJAK Inhibitor (CME/CE)
(MedPage Today) -- Study directly assessed safety, immunogenicity of live zoster vaccine (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - August 29, 2017 Category: Rheumatology Source Type: news

Shingles Vax Effective in RA Patients on JAK Inhibitor (CME/CE)
(MedPage Today) -- Study directly assessed safety, immunogenicity of live zoster vaccine (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 29, 2017 Category: Primary Care Source Type: news